Telavancin
FDA approved · RxLipoglycopeptide antibiotic
Also known as: Vibativ, telavancina, telavancine, Televancin, telavancinum, TD6424
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 17 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Telavancin, sold as Vibativ, is a semisynthetic lipoglycopeptide antibiotic derived from vancomycin. It is thought to kill Gram-positive bacteria by blocking cell wall synthesis and by disrupting the bacterial cell membrane.
What the evidence shows
Telavancin is FDA approved for complicated skin and skin structure infections and for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Gram-positive bacteria, including MRSA. It has 17 registered human trials reaching Phase 4 and about 490 published papers, and known risks include kidney toxicity and potential fetal harm.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Has the era of untreatable infections arrived?
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
Sources
- PubChem compound record (CID 3081362)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.